Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CN1 and CN401 in Relapsed/Refractory Lymphoid Malignancies
NCT04880564Phase 2Terminated
- Sponsor
- Curon Biopharmaceutical
- Start
- Jul 2021
- Primary completion
- Aug 2022
- Countries
- 1
01
Overview
Phase 2, open-label trial of CN201 in lymphoid malignancy, peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL) and 1 more, sponsored by Curon Biopharmaceutical. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 270 days, Maximum Tolerated Dose and/or Recommended Phase II Dose at 21 days and 1 more. Started Jul 2021; status: terminated.
02
Drugs
CN201
03
Conditions
lymphoid malignancyperipheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04880564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04880564.